Community/Retail

Jessica Dunne, PhD, discusses why adult T1D is frequently misdiagnosed as T2D and how autoantibody testing could close the diagnostic gap.

A post hoc analysis of the AT HOME-HF trial found lower hospitalization rates and longer time to admission among patients with diabetes treated with subcutaneous furosemide compared with usual care.

Patients deserve more than marketing. They deserve context.

Alongside medication-specific counseling points, pharmacists can emphasize the importance of a therapeutic home environment.

The Centers for Medicare & Medicaid Services Innovation Center was born to create positive disruption to the financing and delivery of care. Its latest program may be the most likely to succeed (or fail).

Cannabinoids may offer modest, condition-specific analgesic benefits as adjunctive therapy in select chronic pain populations, but current evidence supports a limited role due to inconsistent efficacy, heterogeneity in studies, and safety and pharmacologic concerns.

Medicare’s MTF underpays pharmacy dispensing fees, forcing losses on Part D claims and threatening rural access unless CMS sets realistic, inflation-indexed rate floors.

A poster presented at the 2026 ADA Scientific Sessions underscores the importance of individualized dose titration for patients with type 1 diabetes (T1D) utilizing Technosphere inhaled insulin.

New SYNCHRONIZE data signal broad metabolic and hepatic benefits.

Dave Dixon, PharmD, examines why SGLT2 inhibitor and GLP-1 uptake remain low and how pharmacists can bridge the gap between evidence and implementation.

Expert Lance Sloan, MD, MSE, FACE, FASN, FACP, FEAA, FASPC, discusses CATALYST trial data on mifepristone, glucagon-like peptide-1 receptor agonist (GLP-1 RA) resistance, and screening for hypercortisolism in uncontrolled type 2 diabetes (T2D).

Adding semaglutide to existing regimens in older adults with inadequately controlled T2D significantly reduced HbA1c, fasting blood glucose, body weight, and blood pressure.

Targeted diabetes education improved pharmacists' confidence and competence in addressing clinical inertia, with survey data identifying leading causes of delayed treatment intensification in type 2 diabetes.

John Buse, MD, PhD, breaks down the 2026 American Diabetes Association (ADA) hyperglycemia guidance update, including earlier glucagon-like peptide-1 (GLP-1) receptor agonist and sodium-glucose cotransporter 2 (SGLT-2) inhibitor use and a broader holistic care framework.

Real-world ADA 2026 data shows bempedoic acid add-on lowers major heart risks in type 2 diabetes more than ezetimibe, despite smaller LDL drops.

Jillian Fetzner, MSN, APRN-CNP, described how integrating pharmacists into a collaborative practice agreement processed 3750 diabetes refill requests without provider involvement.

Dave Dixon, PharmD, breaks down the key cardiovascular and kidney risk management updates in the 2026 ADA Standards of Care and what they mean for pharmacy practice.

Both slow and fast transition periods were safe and effective, with minimal adverse events.

A pharmacist-led refill authorization program in endocrinology eliminated 3750 refill requests from provider in-baskets in 2025.

PET scans show long COVID mood and brain fog link to limbic activity, not widespread brain inflammation, reshaping COVID-19 treatment targets.

ADA data show CGM plus pharmacist groups helps seniors with type 2 diabetes prevent hypoglycemia, boost confidence, and prompt safer meds.

The policy direction is clear, but the regulatory mechanics are still working their way through the system.

Recent developments reflect a broader shift toward individualized, biologically informed care.

As retatrutide moves toward FDA submission, Jennifer Goldman, PharmD, breaks down the TRIUMPH-1 data—and what they mean for patient selection, dose escalation counseling, and positioning within the antiobesity pipeline.

The FDA approved the oral antiviral ensitrelvir (Xocova; Shionogi & Co, Ltd) for post-exposure prophylaxis (PEP) of COVID‑19 in adults and adolescents 12 years and older.

Emerging evidence suggests that some individuals develop nutritional deficiencies during treatment, whereas others experience biologically driven GLP-1 resistance.

Pharmacists guide summer safety with sun protection, heat-illness counseling, and travel health tips—quick advice that prevents serious risks.